Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Summary
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.
Competing Interest Statement
N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. All other authors declare no competing interests.
Subject Area
- Biochemistry (10300)
- Bioengineering (7615)
- Bioinformatics (26192)
- Biophysics (13450)
- Cancer Biology (10620)
- Cell Biology (15345)
- Clinical Trials (138)
- Developmental Biology (8453)
- Ecology (12755)
- Epidemiology (2067)
- Evolutionary Biology (16765)
- Genetics (11356)
- Genomics (15400)
- Immunology (10548)
- Microbiology (25044)
- Molecular Biology (10152)
- Neuroscience (54101)
- Paleontology (398)
- Pathology (1655)
- Pharmacology and Toxicology (2877)
- Physiology (4314)
- Plant Biology (9201)
- Synthetic Biology (2541)
- Systems Biology (6752)
- Zoology (1452)